WO2003097108A1 - Preparation medicamenteuse notamment pour le traitement des hernies discales - Google Patents
Preparation medicamenteuse notamment pour le traitement des hernies discales Download PDFInfo
- Publication number
- WO2003097108A1 WO2003097108A1 PCT/FR2003/001412 FR0301412W WO03097108A1 WO 2003097108 A1 WO2003097108 A1 WO 2003097108A1 FR 0301412 W FR0301412 W FR 0301412W WO 03097108 A1 WO03097108 A1 WO 03097108A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preparation
- ethanol
- compound
- formulation
- rays
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention relates to a viscous injectable drug preparation containing in particular ethanol and a compound opaque to X-rays. It applies more particularly, but not exclusively, to the treatment of herniated discs but also to interventional procedures having demonstrated the effectiveness of pure ethanol: treatment of hepatocellular tumors or osteoid osteomas, kidney cysts and arteriovenous angiomas ...
- Herniated discs are the main causes of lower back pain and sciatica. They are most often related to multiple ergonomic and anatomical factors: bad positions, weakness of the abdominal and paraspinal muscles, etc.
- absolute alcohol anhydrous ethanol
- sclerosis of lymph nodes and nerves removal of liver tumors, renal tumors, preoperative treatment of vertebral tumors, peripheral arteriovenous, visceral and brain malformations ...
- alcohol can cause thrombosis of the portal vein by diffusion of the product into the venous system.
- the applicant has, among other things, the objective of avoiding the side effects of ethanol in this pathology, namely the necrosis of healthy tissue due to a diffusion far from the target while increasing its effectiveness.
- an injectable drug preparation comprising at least one compound to give a viscous preparation, ethanol and at least one compound making said preparation opaque to X-rays so as to control its administration. and its action.
- the viscosity makes it possible to limit the diffusion of the preparation to a defined area and to reinforce its therapeutic effect.
- this preparation has the double advantage of proposing an active principle whose diffusion is limited and a marker which makes it possible to better follow the injection during the intervention of the therapist and especially to control after the treatment the exact situation of the product injected at the using a scanner.
- the compounds used to make the preparation opaque to X-rays may be inert compounds such as a tungsten oxide or a tantalum oxide.
- These compounds may be incorporated, for example in the form of a powder, either at the end of the preparation of the preparation, or just before the intervention.
- Ethylcellulose was chosen as the compound (excipient) to obtain the desired viscosity. This choice is based on several criteria:
- the preparation according to the invention meets the essential criteria required which are the safety of use in all the phases of the process, the ability to create a stable and selective sclerosis.
- FIG. 1 represents the measurement of the viscosity expressed in pharmaceutical units as a function of the concentration expressed as a percentage of the weight of ethylcellulose relative to the total weight;
- FIG. 2 represents the measurement of the viscosity expressed in pharmaceutical units as a function of the temperature expressed in degrees Celsius.
- the ethylcellulose is present in a concentration varying from 0.5 to 15%, preferably 5.88% by weight of the total weight of the preparation.
- the preparation was carried out in three stages: gel preparation, aseptic distribution and sterilization of the product in the final packaging.
- the excipient ethylcellulose
- the excipient ethylcellulose
- the whole was left with stirring and with reflux for fifteen minutes, then with stirring until cooling in order to allow the recondensation of the alcohol in the flask.
- the repackaging was then done under a horizontal laminar flow hood in sterile crimped vials of
- the last step in manufacturing the preparation the addition of an opacifying compound powder such as tantalum oxide or tungsten oxide, is done in variable proportion to obtain good opacity.
- This addition can take place either at the end of manufacture before repackaging, or just before performing the intervention.
- these compounds being inert and used in very small quantities, they do not significantly modify the results of the controls presented below and carried out on the preparation before their addition.
- the conformity of the preparation was checked by a sterility test, chemical and physicochemical controls.
- the possible presence of contaminants was sought by seeding 4 ml of the preparation in 250 ml of tryticase-soy broth for aerobic germs, with thioglycolate for anaerobic germs and Sabouraud for yeasts.
- the results of the sterility test confirmed the absence of contaminants in the preparation.
- the alcohol content was determined after dilution of the sample and incorporation of the internal standard, propanol-1, by gas chromatography with detection by flame ionization. The separation is obtained on a Porapak Q column (80-100 "mesh", length 3 m) with nitrogen as the carrier gas (1.2 bar) on a Delsi DN200 device. The alcohol dosage gave a value of 802 gL "1 .
- the specific dosage of the viscosity adjuvant was not carried out, but the concentration was estimated by the dry residue method, an operation which consists in evaporating the ethanol in a tank thermostatically controlled at 110 ° C to constant weight. of the sample.
- the dry residue method made it possible to correlate the theoretical concentration of ethylcellulose with that measured experimentally, ie 5.88% by weight of the total weight of the sample.
- the viscosity of the preparation was measured using a capillary viscometer called Baume (Prolabo). Several series of measurements were carried out at different temperatures and at different concentrations by thickening the preparation. The viscosity measurements showed that, at constant temperature, the viscosity of the preparation increased exponentially with the content of ethylcellulose ( Figure 1). On the other hand, it decreased, always exponentially, when the temperature increased ( Figure 2).
- Table III Physico-chemical parameters as a function of time
- the preparation When injected into a lumbar disc, the preparation made it possible to reduce the intra-disc pressure and thus reduce lumbar pain due to herniated discs.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Massaging Devices (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK03752788T DK1503803T3 (da) | 2002-05-07 | 2003-05-07 | Injicerbar farmaceutisk sammensætning indeholdende ethanol til at behandle diskusprolaps |
US10/513,592 US20070116647A1 (en) | 2002-05-07 | 2003-05-07 | Medicinal preparation particularly for the treatment of slipped discs hernias |
AU2003262617A AU2003262617A1 (en) | 2002-05-07 | 2003-05-07 | Medicinal formulation in particular for treating herniated invertebral discs |
DE60322530T DE60322530D1 (de) | 2002-05-07 | 2003-05-07 | Len |
EP03752788A EP1503803B1 (fr) | 2002-05-07 | 2003-05-07 | Composition pharmaceutique injectable comprenant de l'éthanol pour le traitement des hernies discales |
CA2498976A CA2498976C (fr) | 2002-05-07 | 2003-05-07 | Preparation medicamenteuse notamment pour le traitement des hernies discales |
SI200331368T SI1503803T1 (sl) | 2002-05-07 | 2003-05-07 | Injekcijski farmacevtski sestavek, ki obsega etanol, za zdravljenje prolapsa intervertebralnega diskusa |
HK06102101.6A HK1081849A1 (en) | 2002-05-07 | 2006-02-17 | Medicinal formulation in particular for treating herniated invertebral discs |
US12/870,258 US8153696B2 (en) | 2002-05-07 | 2010-08-27 | Medicinal preparation particularly for the treatment of slipped discs hernias |
US13/681,175 US20130143970A1 (en) | 2002-05-07 | 2012-11-19 | Medicinal preparation particularly for the treatment of slipped discs hernias |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR02/05819 | 2002-05-07 | ||
FR0205819A FR2839450B1 (fr) | 2002-05-07 | 2002-05-07 | Preparation medicamenteuse notamment pour le traitement des hernies discales |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/513,592 A-371-Of-International US20070116647A1 (en) | 2002-05-07 | 2003-05-07 | Medicinal preparation particularly for the treatment of slipped discs hernias |
US12/870,258 Division US8153696B2 (en) | 2002-05-07 | 2010-08-27 | Medicinal preparation particularly for the treatment of slipped discs hernias |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003097108A1 true WO2003097108A1 (fr) | 2003-11-27 |
Family
ID=29286406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2003/001412 WO2003097108A1 (fr) | 2002-05-07 | 2003-05-07 | Preparation medicamenteuse notamment pour le traitement des hernies discales |
Country Status (15)
Country | Link |
---|---|
US (3) | US20070116647A1 (fr) |
EP (1) | EP1503803B1 (fr) |
CN (1) | CN100402020C (fr) |
AT (1) | ATE402719T1 (fr) |
AU (1) | AU2003262617A1 (fr) |
CA (1) | CA2498976C (fr) |
CY (1) | CY1108413T1 (fr) |
DE (1) | DE60322530D1 (fr) |
DK (1) | DK1503803T3 (fr) |
ES (1) | ES2309334T3 (fr) |
FR (1) | FR2839450B1 (fr) |
HK (1) | HK1081849A1 (fr) |
PT (1) | PT1503803E (fr) |
SI (1) | SI1503803T1 (fr) |
WO (1) | WO2003097108A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2839450B1 (fr) * | 2002-05-07 | 2006-04-07 | Aboville Marc D | Preparation medicamenteuse notamment pour le traitement des hernies discales |
FR2891461B1 (fr) * | 2005-09-30 | 2010-09-03 | Jacques Theron | Preparation medicamenteuse visqueuse injectable comprenant de l'ethanol et un compose liposoluble opaque aux rayons x. |
US20200208152A1 (en) | 2017-09-08 | 2020-07-02 | Mina Therapeutics Limited | Stabilized sarna compositions and methods of use |
TW201920669A (zh) | 2017-09-08 | 2019-06-01 | 英商美納治療公司 | HNF4a saRNA組成物和使用方法 |
US20220281911A1 (en) | 2019-08-19 | 2022-09-08 | Mina Therapeutics Limited | Oligonucleotide conjugate compositions and methods of use |
WO2022184176A1 (fr) * | 2021-03-04 | 2022-09-09 | 苏州医本生命科技有限公司 | Composition pharmaceutique contenant de l'éthanol et son utilisation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000071170A1 (fr) * | 1999-05-21 | 2000-11-30 | Micro Therapeutics, Inc. | Nouvelles compositions d'embolisation de grande viscosite |
WO2000071064A1 (fr) * | 1999-05-21 | 2000-11-30 | Micro Therapeutics, Inc. | Methodes d'administration in vivo de compositions d'embolisation de grande viscosite dispersees de maniere uniforme |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2162028A (en) * | 1938-06-25 | 1939-06-13 | Pittsburgh Plate Glass Co | Cellulose ether coating composition |
US2903396A (en) * | 1957-05-08 | 1959-09-08 | Ciba Pharm Prod Inc | Therapeutic compositions and method for treating parkinsonism |
EP0304403A3 (fr) * | 1987-08-21 | 1990-12-12 | Ciba-Geigy Ag | Composition de matière plastique contenant des supraconducteurs |
JPH02157029A (ja) | 1988-12-09 | 1990-06-15 | Dainippon Pharmaceut Co Ltd | アニオン系界面活性剤含有組成物の安定化 |
US5830178A (en) * | 1996-10-11 | 1998-11-03 | Micro Therapeutics, Inc. | Methods for embolizing vascular sites with an emboilizing composition comprising dimethylsulfoxide |
US6476070B2 (en) * | 1997-09-11 | 2002-11-05 | Provasis Therapeutics Inc. | Compositions useful for remodeling body spaces |
US6015541A (en) * | 1997-11-03 | 2000-01-18 | Micro Therapeutics, Inc. | Radioactive embolizing compositions |
US6150022A (en) * | 1998-12-07 | 2000-11-21 | Flex Products, Inc. | Bright metal flake based pigments |
US6355058B1 (en) * | 1999-12-30 | 2002-03-12 | Advanced Cardiovascular Systems, Inc. | Stent with radiopaque coating consisting of particles in a binder |
US20020115904A1 (en) * | 2001-02-21 | 2002-08-22 | Brooke Ren | Magnetically controllable embolic materials |
FR2839450B1 (fr) * | 2002-05-07 | 2006-04-07 | Aboville Marc D | Preparation medicamenteuse notamment pour le traitement des hernies discales |
-
2002
- 2002-05-07 FR FR0205819A patent/FR2839450B1/fr not_active Expired - Lifetime
-
2003
- 2003-05-07 PT PT03752788T patent/PT1503803E/pt unknown
- 2003-05-07 WO PCT/FR2003/001412 patent/WO2003097108A1/fr active IP Right Grant
- 2003-05-07 SI SI200331368T patent/SI1503803T1/sl unknown
- 2003-05-07 US US10/513,592 patent/US20070116647A1/en not_active Abandoned
- 2003-05-07 AU AU2003262617A patent/AU2003262617A1/en not_active Abandoned
- 2003-05-07 DK DK03752788T patent/DK1503803T3/da active
- 2003-05-07 ES ES03752788T patent/ES2309334T3/es not_active Expired - Lifetime
- 2003-05-07 EP EP03752788A patent/EP1503803B1/fr not_active Expired - Lifetime
- 2003-05-07 CN CNB038129361A patent/CN100402020C/zh not_active Expired - Fee Related
- 2003-05-07 AT AT03752788T patent/ATE402719T1/de active
- 2003-05-07 DE DE60322530T patent/DE60322530D1/de not_active Expired - Lifetime
- 2003-05-07 CA CA2498976A patent/CA2498976C/fr not_active Expired - Fee Related
-
2006
- 2006-02-17 HK HK06102101.6A patent/HK1081849A1/xx not_active IP Right Cessation
-
2008
- 2008-10-14 CY CY20081101136T patent/CY1108413T1/el unknown
-
2010
- 2010-08-27 US US12/870,258 patent/US8153696B2/en not_active Expired - Fee Related
-
2012
- 2012-11-19 US US13/681,175 patent/US20130143970A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000071170A1 (fr) * | 1999-05-21 | 2000-11-30 | Micro Therapeutics, Inc. | Nouvelles compositions d'embolisation de grande viscosite |
WO2000071064A1 (fr) * | 1999-05-21 | 2000-11-30 | Micro Therapeutics, Inc. | Methodes d'administration in vivo de compositions d'embolisation de grande viscosite dispersees de maniere uniforme |
Also Published As
Publication number | Publication date |
---|---|
PT1503803E (pt) | 2008-10-16 |
EP1503803B1 (fr) | 2008-07-30 |
HK1081849A1 (en) | 2006-05-26 |
EP1503803A1 (fr) | 2005-02-09 |
FR2839450A1 (fr) | 2003-11-14 |
CA2498976C (fr) | 2011-09-06 |
FR2839450B1 (fr) | 2006-04-07 |
US20100329991A1 (en) | 2010-12-30 |
CN100402020C (zh) | 2008-07-16 |
CA2498976A1 (fr) | 2003-11-27 |
US20070116647A1 (en) | 2007-05-24 |
DK1503803T3 (da) | 2008-11-10 |
CN1665546A (zh) | 2005-09-07 |
ES2309334T3 (es) | 2008-12-16 |
AU2003262617A1 (en) | 2003-12-02 |
DE60322530D1 (de) | 2008-09-11 |
SI1503803T1 (sl) | 2008-12-31 |
US20130143970A1 (en) | 2013-06-06 |
ATE402719T1 (de) | 2008-08-15 |
CY1108413T1 (el) | 2014-02-12 |
US8153696B2 (en) | 2012-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022522540A (ja) | 炎症性皮膚疾患を処置するための局所組成物及び方法 | |
HU229319B1 (en) | Cathartic composition | |
JP5170780B2 (ja) | 眼科における局所用のマクロライド系医薬品組成物 | |
CN110430900A (zh) | 包含赛乐西帕的药物组合物 | |
JP2012211151A (ja) | 疼痛を治療するための組成物および方法 | |
US10842770B2 (en) | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same | |
US8153696B2 (en) | Medicinal preparation particularly for the treatment of slipped discs hernias | |
TWI772659B (zh) | 醫藥配方 | |
CN112823787B (zh) | 一种含有美洛昔康的注射液及其制备方法 | |
CN102038963B (zh) | 制备含有薄荷醇的乳剂的方法 | |
FR2891461A1 (fr) | Preparation medicamenteuse visqueuse injectable comprenant de l'ethanol et un compose liposoluble opaque aux rayons x. | |
WO2003097026A1 (fr) | Inhibiteur du peristaltisme de muscles lisses | |
US11497726B2 (en) | Topical therapy for the treatment of cervical intraepithelial neoplasia (CIN) and cervical cancer using nanoparticles of taxanes | |
WO2005046699A1 (fr) | Article lyophilise contenant de la prostaglandine | |
US4910223A (en) | Low viscosity solvent mixture for dissolution of cholesterol gallstones | |
TWI232102B (en) | A pharmaceutical formulation for injection | |
PG et al. | Formulation and Evaluation of Film Forming Gel of Mometasone Furoate | |
KR102118227B1 (ko) | 척추 투여용 과포화 아세타미노펜 주사 용액 | |
RU2420301C1 (ru) | Способ внутрикостной химиотерапии опухолей позвоночника | |
JP2007077060A (ja) | 注射用の医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2498976 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003752788 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038129361 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003752788 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007116647 Country of ref document: US Ref document number: 10513592 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 10513592 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003752788 Country of ref document: EP |